PMID- 18063127
OWN - NLM
STAT- MEDLINE
DCOM- 20071226
LR  - 20211020
IS  - 1527-3296 (Electronic)
IS  - 0196-6553 (Linking)
VI  - 35
IP  - 10
DP  - 2007 Dec
TI  - The categorization of prior antibiotic use: impact on the identification of risk 
      factors for drug resistance in case control studies.
PG  - 638-42
AB  - BACKGROUND: Analytic approaches to the identification of risk factors for the 
      development of drug resistance vary and may affect study results. Using 
      fluroquinolone-resistant Pseudomonas aeruginosa (FQRPA) and imipenem-resistant P. 
      aeruginosa as models (IRPA), we aimed to examine the effect of different 
      approaches to classification of prior antibiotic use (i.e., class versus 
      spectrum) on the identification of risk factors for antibiotic resistance. 
      METHODS: Case-control studies to identify risk factors for FQRPA and IRPA were 
      performed. In each, two analytic models were utilized. In the first, prior 
      antibiotic use was classified by class, and in the other, prior antibiotic use 
      was classified by spectrum of activity. Risk factors identified by the two models 
      were compared qualitatively for each resistant organism. RESULTS: 879 isolates of 
      P. aeruginosa were included in the case-control studies. Risk factors for FQRPA 
      and IRPA identified in multivariable analyses differed based on which method of 
      classification of prior antibiotic use was utilized. CONCLUSIONS: The 
      identification risk factors for the development of drug-resistant organisms could 
      depend on the method of classification of prior antibiotic use. In studies of 
      risk factors for resistant infections, the approach to classification of prior 
      antibiotic use should be clearly stated and justified.
FAU - Gasink, Leanne B
AU  - Gasink LB
AD  - Division of Infectious Diseases of the Department of Medicine, University of 
      Pennsylvania School of Medicine, Philadelphia, PA, USA. 
      leanne.gasink@uphs.upenn.edu
FAU - Zaoutis, Theoklis E
AU  - Zaoutis TE
FAU - Bilker, Warren B
AU  - Bilker WB
FAU - Lautenbach, Ebbing
AU  - Lautenbach E
LA  - eng
GR  - T32 AI055435/AI/NIAID NIH HHS/United States
GR  - DK-02987-01/DK/NIDDK NIH HHS/United States
GR  - 1K23 AI0629753-01/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Am J Infect Control
JT  - American journal of infection control
JID - 8004854
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Fluoroquinolones)
RN  - 71OTZ9ZE0A (Imipenem)
SB  - IM
MH  - Anti-Bacterial Agents/*classification/therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Drug Resistance, Multiple, Bacterial/*drug effects
MH  - Drug Utilization
MH  - Fluoroquinolones/classification/therapeutic use
MH  - Hospitals, University
MH  - Humans
MH  - Imipenem/classification/therapeutic use
MH  - Odds Ratio
MH  - Pseudomonas Infections/drug therapy
MH  - Pseudomonas aeruginosa/*drug effects
MH  - Retrospective Studies
MH  - Risk Factors
EDAT- 2007/12/08 09:00
MHDA- 2007/12/27 09:00
CRDT- 2007/12/08 09:00
PHST- 2006/09/13 00:00 [received]
PHST- 2007/01/22 00:00 [revised]
PHST- 2007/01/23 00:00 [accepted]
PHST- 2007/12/08 09:00 [pubmed]
PHST- 2007/12/27 09:00 [medline]
PHST- 2007/12/08 09:00 [entrez]
AID - S0196-6553(07)00460-9 [pii]
AID - 10.1016/j.ajic.2007.01.011 [doi]
PST - ppublish
SO  - Am J Infect Control. 2007 Dec;35(10):638-42. doi: 10.1016/j.ajic.2007.01.011.